Correction to “Heparan Sulfate Proteoglycans as Trastuzumab Targets in Anoikis-Resistant Endothelial Cells”

J. O. S. Onyeisi, P. Castanho de Almeida Pernambuco Filho, S. de Araujo Lopes, H. B. Nader, and C. C. Lopes, “Heparan Sulfate Proteoglycans as Trastuzumab Targets in Anoikis-Resistant Endothelial Cells,” Journal of Cellular Biochemistry 120, no. 8 2019: 13826–13840. https://doi.org/10.1002/jcb.28656.

Following the publication of this article, the authors identified errors in Figures 2A and 3A. Specifically, in each figure, one panel was inadvertently duplicated, replacing another panel that should have been included. These duplications occurred due to a technical error during the final stages of image assembly and were unfortunately not detected before publication.

Upon discovering the issue, the authors conducted a thorough review of the original image data and have provided the corrected versions of Figures 2A and 3A below. The corrected figures accurately reflect the intended experimental conditions.

The authors confirm that these errors do not compromise the integrity of the underlying data, nor do they affect the results or conclusions of the study.

We sincerely regret any confusion or inconvenience this may have caused and reaffirm our commitment to upholding the highest standards of scientific accuracy and transparency. We appreciate the editorial team's attention to this matter and remain available to provide any further clarification or supporting documentation as needed.

Author contribution statement

J. O. S. Onyeisi – Investigation, Data Acquisition, Writing – Original Draft

P. Castanho de Almeida Pernambuco Filho – Methodology, Analysis

S. de Araujo Lopes – Data Acquisition, Analysis

H. B. Nader – Supervision

C. C. Lopes – Writing – Review & Editing, Supervision

Corrected Figure 2A:

Corrected Figure 3A:

The authors sincerely apologize for these errors and any confusion it may have caused. We remain committed to maintaining the highest standards of scientific integrity and transparency.